Inside the 7-OH Scheduling Battle: Lobbying, Science, and the Kratom World's Civil War

Why it matters

The fight over whether to ban 7-OH reveals deep divisions not just among users, but among industry groups, scientists, and lobbyists — with millions of dollars, potential conflicts of interest, and millions of users' futures at stake.

The big picture

Following the FDA and HHS recommendation in July 2025 to place 7-OH in Schedule I, the kratom advocacy landscape fractured. The American Kratom Association eventually aligned with the pro-scheduling faction, while newer groups and some researchers pushed back — questioning whether criminalizing the alkaloid will help or harm vulnerable users who depend on it.

Key findings

• FDA recommended DEA classify 7-OH as Schedule I in July 2025, calling it 13 times more potent than morphine
• The AKA and Global Kratom Coalition ultimately supported scheduling, while some scientists and patient advocates opposed it
• Industry group GKC donated $250,000 to University of Florida kratom researchers — a potential conflict of interest critics have flagged
• DEA has received the FDA scheduling request but has not yet announced a timeline or decision
• 13 states and D.C. have already enacted their own 7-OH bans without waiting for federal action
• Some researchers warn scheduling 7-OH could criminalize patients who use it as a harm reduction tool in place of fentanyl

What they say

"The term scheduling is kind of a euphemism for what we know it is. It's criminalizing something. And as someone who has been through the criminal justice system, I do not take that lightly." — Dr. Kirsten Smith, NIDA/Johns Hopkins kratom researcher

Bottom line

The 7-OH scheduling fight has exposed fundamental tensions between public health, research independence, industry influence, and the real-world consequences of drug prohibition for vulnerable users.